Abstract:Abstract Platinum (CP)-resistant ovarian cancer (OC) has few effective treatment options. Adaptive chemotherapy resistance occurs in part through cancer stem cell (CSC) generation. Wnt/beta-catenin signaling is a driver of CSC survival via induction of gene expression, including aldehyde dehydrogenase (ALDH) enzymes. The gene for focal adhesion kinase (FAK) is commonly amplified in advance-stage OC and this is associated with decreased patient survival. How FAK is activated in OC and whether this is connected to CSC survival is unknown. Here, we find that FAK Y397 phosphorylation (a marker of FAK activation) is increased in non-necrotic Pax8-positive OC tumor tissue after neo-adjuvant chemotherapy compared to paired pre-treatment tumor biopsy samples. FAK activation occurs after CP plus paclitaxel treatment of xenograft tumors, within 60 min of CP treatment of OC cells, and FAK Y397 levels are constitutively-elevated in OC cells pre-adapted to exhibit elevated CP resistance. Pharmacological FAK inhibition (VS-4718, 0.1 µM) selectively prevented CP-resistant tumorsphere formation in vitro and combined with CP to promote cell apoptosis. Combinatorial VS-4718, CP, and paclitaxel chemotherapy exhibited additive inhibitory effects in preventing CP-resistant tumor growth in mice. VS-4718 monotherapy of tumor-bearing mice reduced tumor-associated ALDH activity and resulted in an 85-fold reduction in secondary tumors formed in limiting dilution assays. CRISPR-mediated FAK knockout in OVCAR3 cells combined with stable re-expression of FAK wildtype or a kinase-inactive FAK (K454R) mutant revealed that intrinsic FAK activity was essential for beta-catenin activation, ALDH-1A1 expression, and OVCAR3 tumorsphere growth. As activated constructs of beta-catenin but not YAP1 rescued FAK KO OVCAR3 phenotypes, these studies provide important insights into a FAK signaling linkage to beta-catenin in promoting CSC survival and adaptive resistance to CP chemotherapy. These studies provide the foundational support for a Phase I-II clinical trial for treatment of recurrent platinum-resistant ovarian cancer (NCT03287271) termed ROCKIF: Re-sensitization of carboplatin-resistant Ovarian Cancer by Kinase Inhibition of FAK. As FAK is activated in tumor cells surviving carboplatin-paclitaxel chemotherapy, co-targeting of this FAK/beta-catenin adaptive resistance pathway may expose a vulnerability of CP-resistant tumors. Citation Format: Carlos J. Diaz Osterman, Lisa M. Bean, Florian J. Sulzmaier, Kristin N. Taylor, Shulin A. Jiang, Isabelle Tancioni, Kristen Anderson, Christine Jean, Xiao Lei Chen, Elizabeth G. Kleinschmidt, Vihren N. Kolev, David T. Weaver, Jonathan A. Pachter, Denise C. Connolly, Alfredo Molinolo, David D. Schlaepfer. Vulnerability of platinum-resistant ovarian cancer to FAK inhibition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1991.

FAK Inhibition Disrupts a Β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth

Abstract 752: Genetic and Pharmacological FAK Inhibition Disrupt a Β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth

Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression

Supplementary Figure 2 from FAK Inhibition Disrupts a Β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth

Abstract 3814: FAK Inhibition Targets Nucleostemin, a Nucleolar Protein, Impacting Breast Cancer Spheroid Growth and Tumor Progression

Abstract 3812: FAK Inhibition Resensitizes Platinum-Resistant Serous Ovarian Cancer

FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways

Supplementary Figure 1 from FAK Inhibition Disrupts a Β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

Supplementary Table 1 from FAK Inhibition Disrupts a Β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth

Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis

Focal Adhesion Kinase (FAK) Controls Programmed Death-Ligand-1 (PD-L1) Expression and Promotes Tumor Immune Evasion in a Syngeneic Murine Model of Epithelial Ovarian Cancer

Abstract 1991: Vulnerability of Platinum-Resistant Ovarian Cancer to FAK Inhibition

FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest

Inhibition of the Integrin/fak Signaling Axis and C-Myc Synergistically Disrupts Ovarian Cancer Malignancy

Abstract B39: Inhibiting Endothelial FAK Activity Blocks Tumor Cell Extravasation

Focal adhesion kinase signaling - tumor vulnerabilities and clinical opportunities

FAK Activity Protects Nucleostemin in Facilitating Breast Cancer Spheroid and Tumor Growth

Abstract 3666: Follicle-stimulating Hormone Inhibits Apoptosis and Autophagy in Ovarian Cancer Cells by Activating Survivin and Rab25

Targeting ILK and Β4 Integrin Abrogates the Invasive Potential of Ovarian Cancer.